Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs.

Related Keywords

Connecticut ,United States ,New Haven ,American ,Samer Zeidan ,Daiichi Sankyo ,States Cerner Enviza ,Boehringer Ingelheim Incyte ,Myeloid Malignancies At Yale Cancer Center ,Early Therapeutics Research ,Clinical Research Team For Leukemias ,American Society Of Hematology ,Novartis ,Genentech ,Pfizer ,Amgen ,Annual Meeting ,Clinical Research Team ,Myeloid Malignancies ,Yale Cancer Center ,End Results ,United States Cerner Enviza ,Charlson Comorbidity Index ,Medicare Advantage ,Seattle Genetics ,Lox Oncology ,Shattuck Labs ,Lymphoma Myeloma ,